{"entity":{"id":"radotinib","kind":"drug","name":"Radotinib","aka":["Supect"],"tldr":"Radotinib is an oral kinase inhibitor from Il-Yang Pharm. Co., Ltd., in registered phase 3 trials for chronic myeloid leukaemia.","summary":"Radotinib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 3 trial sponsored by Il-Yang Pharm. Co., Ltd., in chronic myeloid leukaemia. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-3","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Radotinib","url":"https://clinicaltrials.gov/search?intr=Radotinib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["cml","cml-chronic-phase"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["il-yang-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03722420","nct03459534"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral kinase inhibitor","mechanism":"A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/radotinib/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/"}],"company":[{"id":"il-yang-pharmaceutical","kind":"company","name":"Il-Yang Pharmaceutical","route":"/companies/il-yang-pharmaceutical/"}],"trial":[{"id":"nct03459534","kind":"trial","name":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","route":"/trials/nct03459534/"},{"id":"nct03722420","kind":"trial","name":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","route":"/trials/nct03722420/"}]}}